Rathbones Group’s Iovance Biotherapeutics IOVA Stock Holding History

Rathbones Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.5K	Hold	12,854	–	–	﹤0.01%	654
2026 Q1	$45.1K	Hold	12,854	–	–	﹤0.01%	636
2025 Q4	$35.1K	Sell	12,854 -300	-2%	-$694	﹤0.01%	624
2025 Q3	$28.5K	Hold	13,154	–	–	﹤0.01%	633
2025 Q2	$22.6K	Sell	13,154 -60,000	-82%	-$149K	﹤0.01%	620
2025 Q1	$244K	Hold	73,154	–	–	﹤0.01%	498
2024 Q4	$541K	Hold	73,154	–	–	﹤0.01%	405
2024 Q3	$687K	Hold	73,154	–	–	﹤0.01%	371
2024 Q2	$587K	Hold	73,154	–	–	﹤0.01%	389
2024 Q1	$1.08M	Buy	73,154 +2,000	+3%	+$23.3K	0.01%	318
2023 Q4	$578K	Hold	71,154	–	–	﹤0.01%	376
2023 Q3	$324K	Buy	+71,154	New	+$465K	﹤0.01%	463

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Rathbones Group's IOVA Position: Q2 2026 in Review

Rathbones Group held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 12,854 shares worth $53.5K. The position accounts for ﹤0.01% of the portfolio, ranked #654.

Rathbones Group first reported a position in IOVA in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.08M in Q1 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Rathbones Group held 12,854 shares of Iovance Biotherapeutics worth $53.5K as of Q2 2026.
Rathbones Group left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up ﹤0.01% of Rathbones Group's portfolio in Q2 2026, its #654 holding.
Rathbones Group first reported a position in Iovance Biotherapeutics in Q3 2023 and has held it in 12 quarters since.
Rathbones Group's Iovance Biotherapeutics position peaked at $1.08M in Q1 2024.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.